BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//UCLA - ECPv5.14.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:UCLA
X-ORIGINAL-URL:https://www.chemistry.ucla.edu
X-WR-CALDESC:Events for UCLA
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20210128T160000
DTEND;TZID=America/Los_Angeles:20210128T160000
DTSTAMP:20260618T194229
CREATED:20210112T010611Z
LAST-MODIFIED:20210112T010611Z
UID:13416-1611849600-1611849600@www.chemistry.ucla.edu
SUMMARY:Prioritizing the patient - The discovery of lorlatinib\, a macrocyclic ALK inhibitor for the treatment of resistant and metastatic NSCLC
DESCRIPTION:Abstract: Primary and secondary mutations in anaplastic lymphoma kinase (ALK) are oncogenic. Insights into ALK acquired resistance were used to define a drug design strategy that led to the discovery of lorlatinib (Lorbrena; PF-06463922)\, a novel ATP-competitive macrocyclic inhibitor of ALK and ROS1 kinases. Structure based drug design\, lipophilic efficiency and physicochemical property-based optimization provided inhibitors with overlapping broad-spectrum potency\, low transporter efflux\, and brain penetration. The small\, cyclic design provided a unique structure with unique properties. NMR and other analytical methods were used to study the unique molecular properties\, including atropisomerism for some analogues. Protein dynamics from x-ray crystallographic data and molecular dynamics simulations performed on ALK mutants shed light on the mechanisms of acquired resistance. Research culminated in the discovery of a first in patient candidate\, Lorbrena\, which was given Breakthrough Therapy status by the FDA in 2016 and approved in late 2018 for the treatment of patients with refractory ALK positive non-small cell lung cancer (NSCLC). Lorbrena is the first and only ALK tyrosine kinase inhibitor (TKI) approved for use after second-generation ALK TKIs. Recently\, a Phase 3 study of Lorbrena in patients with previously untreated ALK-positive\, advanced NSCLC met its primary endpoint by demonstrating significantly improved progression-free survival\, as compared to Xalkori\, which is currently primary standard of care. The FDA has accepted for Priority Review the supplemental New Drug Application (sNDA) for Lorbrena as a first-line treatment for patients with ALK-positive NSCLC based on the pivotal data from the CROWN study.
URL:https://www.chemistry.ucla.edu/seminars/prioritizing-patient-discovery-lorlatinib-macrocyclic-alk-inhibitor-treatment-resistant-and/
CATEGORIES:Organic Colloquium,Seminars
END:VEVENT
END:VCALENDAR